AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
Phase 3
Completed
- Conditions
- Dyslipidaemia
- First Posted Date
- 2008-04-08
- Last Posted Date
- 2009-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT00654602
Compare the Safety & Efficacy of Rosuvastatin 40mg in Combination With Ezetimibe 10mg
Phase 3
Completed
- Conditions
- HypercholesterolemiaCoronary Heart DiseaseAtherosclerosis
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00653445
Treatment of Hypercholesterolaemia in Hispanic Subjects (STARSHIP)
Phase 3
Completed
- Conditions
- HypercholesterolemiaDyslipidaemia
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3000
- Registration Number
- NCT00653965
Treatment of Hypercholesterolaemia in South Asian Subjects (IRIS)
Phase 3
Completed
- Conditions
- HypercholesterolemiaDyslipidaemia
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2340
- Registration Number
- NCT00654225
Comparing the Efficacy and Safety of Rosuvastatin With Atorvastatin and Simvastatin (SOLAR)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4444
- Registration Number
- NCT00654173
OLE Study to Evaluate Safety / Efficacy of ZD4522
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3500
- Registration Number
- NCT00654303
Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 Weeks
Phase 3
Completed
- Conditions
- HypercholesterolemiaCoronary Heart Disease
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00653588
Rosuvastatin Versus Atorvastatin in the Treatment of Hypercholesterolaemia in African American Subjects(ARIES)
Phase 3
Completed
- Conditions
- HypercholesterolemiaDyslipidaemia
- Interventions
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1700
- Registration Number
- NCT00653744
Symbicort in Asthmatic Children - SEEDLING
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2009-03-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 405
- Registration Number
- NCT00651547
Efficacy of Symbicort pMDI Administered Once Daily in Adolescents and Adults During 12 Weeks - STEM
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: budesonide/formoterol
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00652392
© Copyright 2025. All Rights Reserved by MedPath